2.07
In 8 Bio Inc stock is traded at $2.07, with a volume of 41,998.
It is down -1.90% in the last 24 hours and up +3.50% over the past month.
IN8bio Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of gamma-delta T cell product candidates for solid and liquid tumors, by employing allogeneic, autologous, and genetically modified gamma-delta T cells. Its product candidates include INB-400, for the treatment of newly diagnosed glioblastoma, or GBM, INB-100 for the treatment of patients with high-risk leukemias undergoing hematopoietic stem cell transplantation, and other product candidates such as INB-200, INB-300, and INB-500.
See More
Previous Close:
$2.11
Open:
$2.0501
24h Volume:
41,998
Relative Volume:
0.54
Market Cap:
$9.40M
Revenue:
-
Net Income/Loss:
$-31.88M
P/E Ratio:
-2.76
EPS:
-0.75
Net Cash Flow:
$-25.20M
1W Performance:
-1.43%
1M Performance:
+3.50%
6M Performance:
-57.12%
1Y Performance:
-70.01%
In 8 Bio Inc Stock (INAB) Company Profile
Name
In 8 Bio Inc
Sector
Industry
Phone
(646) 600-6438
Address
EMPIRE STATE BUILDING, NEW YORK
Compare INAB with other stocks
Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
---|---|---|---|---|---|---|
![]()
INAB
In 8 Bio Inc
|
2.07 | 9.58M | 0 | -31.88M | -25.20M | -0.75 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
416.81 | 104.76B | 11.39B | 3.64B | 3.50B | 13.99 |
![]()
ALNY
Alnylam Pharmaceuticals Inc
|
481.67 | 63.06B | 2.46B | -319.09M | -52.09M | -2.4669 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
578.05 | 60.32B | 14.21B | 4.46B | 3.56B | 39.69 |
![]()
ARGX
Argen X Se Adr
|
843.66 | 51.55B | 3.06B | 1.28B | 447.35M | 19.67 |
![]()
INSM
Insmed Inc
|
165.76 | 34.49B | 398.11M | -1.03B | -868.57M | -5.7032 |
In 8 Bio Inc Stock (INAB) Upgrades & Downgrades
Date | Action | Analyst | Rating Change |
---|---|---|---|
Mar-18-24 | Initiated | Laidlaw | Buy |
Aug-30-22 | Initiated | H.C. Wainwright | Buy |
In 8 Bio Inc Stock (INAB) Latest News
Climb Bio Publishes Long-Term Data on Budoprutug - TradingView
PALI back in Nasdaq bid-price compliance; 133.0M shares out - Stock Titan
[8-K] Inmune Bio, Inc. Reports Material Event | INMB SEC FilingForm 8-K - Stock Titan
[8-K] Annovis Bio, Inc. Reports Material Event | ANVS SEC FilingForm 8-K - Stock Titan
[8-K] – Inmune Bio, Inc. (INMB) (CIK 0001711754) - Stock Titan
Inmune Bio Inc Announces Participation in Dermatologic Panel - TradingView
Oct 22 CEO Panel: INmune Bio's CORDStrom for RDEB — David Moss at Maxim Growth Summit in NYC - Stock Titan
Palisade Bio Granted Canadian Patent Covering Composition of Lead Product Candidate PALI-2108 - GlobeNewswire
Is Mustang Bio Inc. stock ready for a breakoutJuly 2025 Closing Moves & Free Low Drawdown Momentum Trade Ideas - newser.com
OrbiMed Funds Buy into Adicet Bio Offering; Ownership Diluted to 9.6% - Stock Titan
Layoff Tracker: Ferring To Cut 500 Employees as Part of Business Model Shift - BioSpace
Korro Bio, Inc. (KRRO) Stock Price, News, Quote & History - Yahoo
Palisade Bio, Inc. Cancels Special Meeting of Stockholders - TradingView
[8-K] PALISADE BIO, INC. Reports Material Event | PALI SEC FilingForm 8-K - Stock Titan
[SCHEDULE 13G] PALISADE BIO, INC. SEC Filing - Stock Titan
Perceptive Discloses 9.99% Stake in Palisade Bio (12.24M Shares) - Stock Titan
PALI grants 7,665,800 RSUs to Chief Medical Officer; vesting over 2 years - Stock Titan
PALI Form 4: 9.18M RSUs granted to director/officer - Stock Titan
Bio, semiconductor, content firms to reboot Korea’s IPO market - KED Global
Deep Track discloses 6.43M pre-funded warrants, holds 9.99% of PALI - Stock Titan
Nuvation Bio Inc. (NUVB): A Bull Case Theory - Insider Monkey
PlayStation sale round-up for North America October 8, 2025 - TrueTrophies
Brokerages Set Gossamer Bio, Inc. (NASDAQ:GOSS) Price Target at $8.50 - Defense World
[8-K] Adicet Bio, Inc. Reports Material Event | ACET SEC FilingForm 8-K - Stock Titan
Morning Market Movers: SPRB, LXEO, BMEA, Seeing Big Swings - RTTNews
70.0M shares: Adicet Bio Prices $80M Registered Direct Offering - Stock Titan
Adicet's ADI-001 yields immune-reset signals; Phase 2 targeted Q2 2026 - Stock Titan
Morning Market Movers: DBVT, CLPT, DWTX, Seeing Big Swings - RTTNews
$138M Raised: Palisade Bio Closes Upsized Offering to Fund Phase 2 PALI-2108 - Stock Titan
Biopsy Devices Market Poised for Steady Growth by 2032, Fueled by Innovation and Increasing Surgical Procedures | DelveInsight - The Globe and Mail
Palisade Bio Inc. (PALI) Stock Price | Live Quotes & Charts | NSC - StocksToTrade
Mucopolysaccharidosis III Pipeline 2025: Pioneering Clinical - openPR.com
Wheeler Bio Appoints Jay Benson as Chief Operating Officer - PR Newswire
Palisade Bio Announces Pricing of Upsized $120 Million Underwritten Public Offering of Common Stock - Yahoo Finance
Biotech Adicet Bio Issues New Employee Stock Options at $0.81 Under Special Inducement Plan - Stock Titan
Cancer Detection Biotech bioAffinity Technologies Raises $4.8M Through Public Stock Offering at $2.50 - Stock Titan
United Natural Foods Posts Upbeat Results, Joins AnaptysBio, Semtech, UiPath And Other Big Stocks Moving Higher On Tuesday - Benzinga
180-Patient Phase 3 Trial: Nuvation Bio Tests IBTROZI for Early-Stage Lung Cancer Prevention - Stock Titan
Climb Bio stock price target raised to $8 from $7 at BTIG on CLYM116 potential - Investing.com India
24-Week TSLP Inhibition: Upstream Bio's Verekitug Shows Breakthrough Respiratory Disease Treatment Data - Stock Titan
KALA BIO Announces Topline Results from CHASE Phase 2b - GlobeNewswire
KALA BIO Announces Topline Results from CHASE Phase 2b Clinical Trial Evaluating KPI-012 for the Treatment of Persistent Corneal Epithelial Defect (PCED) Did Not Meet Primary Endpoint - Yahoo Finance
Climb Bio Announces CLYM116 Preclinical Data Highlighting Potential for Best-In-Class Therapeutic for IgAN - GlobeNewswire
Published on: 2025-09-27 16:04:15 - newser.com
What the charts say about Instil Bio Inc. todayBull Run & Weekly High Potential Stock Alerts - newser.com
What analysts say about INmune Bio Inc stockTechnical Breakout Signals & Free Daily Stock Hotspot Analysis - Early Times
Can Climb Bio Inc. recover in the next quarter2025 Market Overview & AI Enhanced Execution Alerts - newser.com
Gossamer Bio Announces Presentations at the European Respiratory Society (ERS) Congress 2025 - Business Wire
Cabaletta Bio, Inc. $CABA Shares Purchased by Acadian Asset Management LLC - MarketBeat
INmune Bio, Inc. (NASDAQ:INMB) Short Interest Down 29.8% in August - MarketBeat
Co-Diagnostics, Inc. Announces Closing of $3.8 Million Registered Direct Offering of Common Stock Priced At-The-Market Under Nasdaq Rules - BioSpace
In 8 Bio Inc Stock (INAB) Financials Data
Revenue
Net Income
Cash Flow
EPS
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):